Clinical applications of the CellSearch platform in cancer patients

Advanced Drug Delivery Reviews

Volumn 125, Issue , 2018, Pages 102-121

  Riethdorf, Sabine ^a   O'Flaherty, Linda ^a,b   Hille, Claudia ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Breast cancer; CellSearch ; Circulating tumor cells (CTCs); Gastrointestinal tumors; Lung cancer; Molecular characterization of single CTCs; Urological tumors

Indexed keywords

DISEASES; GENES;

BREAST CANCER; CIRCULATING TUMOR CELLS; CLINICAL APPLICATION; EPIGENETIC ALTERATIONS; LUNG CANCER; MECHANISMS OF RESISTANCES; MOLECULAR CHARACTERIZATION; THERAPEUTIC STRATEGY;

TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; NIVOLUMAB; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BLOOD SAMPLING; BREAST CANCER; CANCER CELL; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; COLORECTAL CANCER; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GERM CELL TUMOR; HER2 GENE; HUMAN; IMAGE ANALYSIS; KIDNEY CANCER; LIVER CELL CARCINOMA; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RELIABILITY; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; STOMACH CANCER; SURVIVAL TIME; TESTICULAR GERM CELL TUMOR; TRANSCRIPTION REGULATION; BLOOD; CELL SEPARATION; NEOPLASM; PATHOLOGY; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CELL SEPARATION; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 85044525388     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2018.01.011     Document Type: Review

References (301)

1. Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6 (2016), 479–491.
2. Rack, B., Schindlbeck, C., Juckstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T.W., Lorenz, R., Tesch, H., Fasching, P.A., Fehm, T., Schneeweiss, A., Lichtenegger, W., Beckmann, M.W., Friese, K., Pantel, K., Janni, W., S.S. Group, Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst., 106, 2014.
3. Riethdorf, S., Muller, V., Loibl, S., Nekljudova, V., Weber, K., Huober, J., Fehm, T., Schrader, I., Hilfrich, J., Holms, F., Tesch, H., Schem, C., von Minckwitz, G., Untch, M., Pantel, K., Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin. Cancer Res. 23 (2017), 5384–5393.
4. Pierga, J.Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Dieras, V., Rolland, E., Mignot, L., Mathiot, C., Bidard, F.C., High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 23 (2012), 618–624.
5. Alix-Panabieres, C., Bartkowiak, K., Pantel, K., Functional studies on circulating and disseminated tumor cells in carcinoma patients. Mol. Oncol. 10 (2016), 443–449.
6. Pantel, K., Alix-Panabieres, C., The clinical significance of circulating tumor cells. Nat. Clin. Pract. Oncol. 4 (2007), 62–63.
7. Pantel, K., Blood-based analysis of circulating cell-free DNA and tumor cells for early cancer detection. PLoS Med., 13, 2016, e1002205.
8. Pantel, K., Alix-Panabieres, C., Liquid biopsy: potential and challenges. Mol. Oncol. 10 (2016), 371–373.
9. Schwarzenbach, H., Hoon, D.S., Pantel, K., Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11 (2011), 426–437.
10. Bardelli, A., Pantel, K., Liquid biopsies, what we do not know (yet). Cancer Cell 31 (2017), 172–179.
11. Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., Singh, S., Williams, C., Soplop, N., Uryu, K., Pharmer, L., King, T., Bojmar, L., Davies, A.E., Ararso, Y., Zhang, T., Zhang, H., Hernandez, J., Weiss, J.M., Dumont-Cole, V.D., Kramer, K., Wexler, L.H., Narendran, A., Schwartz, G.K., Healey, J.H., Sandstrom, P., Labori, K.J., Kure, E.H., Grandgenett, P.M., Hollingsworth, M.A., de Sousa, M., Kaur, S., Jain, M., Mallya, K., Batra, S.K., Jarnagin, W.R., Brady, M.S., Fodstad, O., Muller, V., Pantel, K., Minn, A.J., Bissell, M.J., Garcia, B.A., Kang, Y., Rajasekhar, V.K., Ghajar, C.M., Matei, I., Peinado, H., Bromberg, J., Lyden, D., Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
12. Joosse, S.A., Gorges, T.M., Pantel, K., Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol. Med. 7 (2015), 1–11.
13. Alix-Panabieres, C., Pantel, K., Challenges in circulating tumour cell research. Nat. Rev. Cancer 14 (2014), 623–631.
14. Pantel, K., Alix-Panabieres, C., Liquid biopsy in 2016: circulating tumour cells and cell-free DNA in gastrointestinal cancer. Nat. Rev. Gastroenterol. Hepatol. 14 (2017), 73–74.
15. Swennenhuis, J.F., van Dalum, G., Zeune, L.L., Terstappen, L.W., Improving the CellSearch(R) system. Expert. Rev. Mol. Diagn. 16 (2016), 1291–1305.
16. Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M., Doyle, G.V., Allard, W.J., Terstappen, L.W., Hayes, D.F., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (2004), 781–791.
17. de Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H., Doyle, G.V., Terstappen, L.W., Pienta, K.J., Raghavan, D., Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14 (2008), 6302–6309.
18. Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M., Mitchell, E., Miller, M.C., Doyle, G.V., Tissing, H., Terstappen, L.W., Meropol, N.J., Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008), 3213–3221.
19. Tibbe, A.G., Miller, M.C., Terstappen, L.W., Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71 (2007), 154–162.
20. Ligthart, S.T., Coumans, F.A., Attard, G., Cassidy, A.M., de Bono, J.S., Terstappen, L.W., Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One, 6, 2011, e27419.
21. Martin, M., Garcia-Saenz, J.A., Maestro De las Casas, M.L., Vidaurreta, M., Puente, J., Veganzones, S., Rodriguez-Lajusticia, L., De la Orden, V., Oliva, B., De la Torre, J.C., Lopez-Tarruella, S., Casado, A., Sastre, J., Diaz-Rubio, E., Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. Anticancer Res. 29 (2009), 4185–4187.
22. Rao, C.G., Chianese, D., Doyle, G.V., Miller, M.C., Russell, T., Sanders, R.A. Jr., Terstappen, L.W., Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol. 27 (2005), 49–57.
23. Allard, W.J., Matera, J., Miller, M.C., Repollet, M., Connelly, M.C., Rao, C., Tibbe, A.G., Uhr, J.W., Terstappen, L.W., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10 (2004), 6897–6904.
24. Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Janicke, F., Jackson, S., Gornet, T., Cristofanilli, M., Pantel, K., Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13 (2007), 920–928.
25. Ligthart, S.T., Coumans, F.A., Bidard, F.C., Simkens, L.H., Punt, C.J., de Groot, M.R., Attard, G., de Bono, J.S., Pierga, J.Y., Terstappen, L.W., Circulating tumor cells count and morphological features in breast, colorectal and prostate cancer. PLoS One, 8, 2013, e67148.
26. Went, P.T., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., Dirnhofer, S., Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35 (2004), 122–128.
27. Liberti, P.A., Rao, C.G., Terstappen, L.W.M., Optimization of ferrofluids and protocols for the enrichment of breast tumor cells in blood. J. Magn. Mater. 225 (2001), 301–307.
28. Mostert, B., Kraan, J., Bolt-de Vries, J., van der Spoel, P., Sieuwerts, A.M., Schutte, M., Timmermans, A.M., Foekens, R., Martens, J.W., Gratama, J.W., Foekens, J.A., Sleijfer, S., Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 127 (2011), 33–41.
29. Onstenk, W., Kraan, J., Mostert, B., Timmermans, M.M., Charehbili, A., Smit, V.T., Kroep, J.R., Nortier, J.W., van de Ven, S., Heijns, J.B., Kessels, L.W., van Laarhoven, H.W., Bos, M.M., van de Velde, C.J., Gratama, J.W., Sieuwerts, A.M., Martens, J.W., Foekens, J.A., Sleijfer, S., Improved circulating tumor cell detection by a combined EpCAM and MCAM CellSearch enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy. Mol. Cancer Ther. 14 (2015), 821–827.
30. Bitting, R.L., Boominathan, R., Rao, C., Kemeny, G., Foulk, B., Garcia-Blanco, M.A., Connelly, M., Armstrong, A.J., Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 64 (2013), 129–136.
31. Zhang, T., Boominathan, R., Foulk, B., Rao, C., Kemeny, G., Strickler, J.H., Abbruzzese, J.L., Harrison, M.R., Hsu, D.S., Healy, P., Li, J., Pi, C., Prendergast, K.M., Hobbs, C., Gemberling, S., George, D.J., Hurwitz, H.I., Connelly, M., Garcia-Blanco, M.A., Armstrong, A.J., Development of a Novel c-MET-based CTC detection platform. Mol. Cancer Res. 14 (2016), 539–547.
32. Rao, C., Bui, T., Connelly, M., Doyle, G., Karydis, I., Middleton, M.R., Clack, G., Malone, M., Coumans, F.A., Terstappen, L.W., Circulating melanoma cells and survival in metastatic melanoma. Int. J. Oncol. 38 (2011), 755–760.
33. Kraan, J., Sleijfer, S., Strijbos, M.H., Ignatiadis, M., Peeters, D., Pierga, J.Y., Farace, F., Riethdorf, S., Fehm, T., Zorzino, L., Tibbe, A.G., Maestro, M., Gisbert-Criado, R., Denton, G., de Bono, J.S., Dive, C., Foekens, J.A., Gratama, J.W., External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin. Cytom. 80 (2011), 112–118.
34. Ignatiadis, M., Riethdorf, S., Bidard, F.C., Vaucher, I., Khazour, M., Rothe, F., Metallo, J., Rouas, G., Payne, R.E., Coombes, R., Teufel, I., Andergassen, U., Apostolaki, S., Politaki, E., Mavroudis, D., Bessi, S., Pestrin, M., Di Leo, A., Campion, M., Reinholz, M., Perez, E., Piccart, M., Borgen, E., Naume, B., Jimenez, J., Aura, C., Zorzino, L., Cassatella, M., Sandri, M., Mostert, B., Sleijfer, S., Kraan, J., Janni, W., Fehm, T., Rack, B., Terstappen, L., Repollet, M., Pierga, J.Y., Miller, C., Sotiriou, C., Michiels, S., Pantel, K., International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res., 16, 2014, R43.
35. Ignatiadis, M., Rack, B., Rothe, F., Riethdorf, S., Decraene, C., Bonnefoi, H., Dittrich, C., Messina, C., Beauvois, M., Trapp, E., Goulioti, T., Tryfonidis, K., Pantel, K., Repollet, M., Janni, W., Piccart, M., Sotiriou, C., Litiere, S., Pierga, J.Y., Liquid biopsy-based clinical research in early breast cancer: the EORTC 90091-10093 Treat CTC trial. Eur. J. Cancer 63 (2016), 97–104.
36. Fehm, T., Muller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Lohberg, C.R., Solomayer, E., Rack, B., Riethdorf, S., Klein, C., Schindlbeck, C., Brocker, K., Kasimir-Bauer, S., Wallwiener, D., Pantel, K., HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 124 (2010), 403–412.
37. Schramm, A., Friedl, T.W., Schochter, F., Scholz, C., de Gregorio, N., Huober, J., Rack, B., Trapp, E., Alunni-Fabbroni, M., Muller, V., Schneeweiss, A., Pantel, K., Meier-Stiegen, F., Hartkopf, A., Taran, F.A., Wallwiener, D., Janni, W., Fehm, T., Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch. Gynecol. Obstet. 293 (2016), 271–281.
38. Deutsch, T.M., Riethdorf, S., Nees, J., Hartkopf, A.D., Schonfisch, B., Domschke, C., Sprick, M.R., Schutz, F., Brucker, S.Y., Stefanovic, S., Sohn, C., Pantel, K., Trumpp, A., Schneeweiss, A., Wallwiener, M., Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Breast Cancer Res. Treat. 160 (2016), 277–290.
39. Coumans, F.A., Doggen, C.J., Attard, G., de Bono, J.S., Terstappen, L.W., All circulating EpCAM+CK+CD45− objects predict overall survival in castration-resistant prostate cancer. Ann. Oncol. 21 (2010), 1851–1857.
40. McDaniel, A.S., Ferraldeschi, R., Krupa, R., Landers, M., Graf, R., Louw, J., Jendrisak, A., Bales, N., Marrinucci, D., Zafeiriou, Z., Flohr, P., Sideris, S., Crespo, M., Figueiredo, I., Mateo, J., de Bono, J.S., Dittamore, R., Tomlins, S.A., Attard, G., Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. BJU Int. 120:5B (2017), E30–E44.
41. Jansson, S., Bendahl, P.O., Larsson, A.M., Aaltonen, K.E., Ryden, L., Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer, 16, 2016, 433.
42. Mu, Z., Wang, C., Ye, Z., Austin, L., Civan, J., Hyslop, T., Palazzo, J.P., Jaslow, R., Li, B., Myers, R.E., Jiang, J., Xing, J., Yang, H., Cristofanilli, M., Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res. Treat. 154 (2015), 563–571.
43. Scholtens, T.M., Schreuder, F., Ligthart, S.T., Swennenhuis, J.F., Tibbe, A.G., Greve, J., Terstappen, L.W., CellTracks TDI: an image cytometer for cell characterization. Cytometry A 79 (2011), 203–213.
44. Scholtens, T.M., Schreuder, F., Ligthart, S.T., Swennenhuis, J.F., Greve, J., Terstappen, L.W., Automated identification of circulating tumor cells by image cytometry. Cytometry A 81 (2012), 138–148.
45. Andree, K.C., van Dalum, G., Terstappen, L.W., Challenges in circulating tumor cell detection by the CellSearch system. Mol. Oncol. 10 (2016), 395–407.
46. Crespo, M., van Dalum, G., Ferraldeschi, R., Zafeiriou, Z., Sideris, S., Lorente, D., Bianchini, D., Rodrigues, D.N., Riisnaes, R., Miranda, S., Figueiredo, I., Flohr, P., Nowakowska, K., de Bono, J.S., Terstappen, L.W., Attard, G., Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br. J. Cancer 112 (2015), 1166–1174.
47. Polzer, B., Medoro, G., Pasch, S., Fontana, F., Zorzino, L., Pestka, A., Andergassen, U., Meier-Stiegen, F., Czyz, Z.T., Alberter, B., Treitschke, S., Schamberger, T., Sergio, M., Bregola, G., Doffini, A., Gianni, S., Calanca, A., Signorini, G., Bolognesi, C., Hartmann, A., Fasching, P.A., Sandri, M.T., Rack, B., Fehm, T., Giorgini, G., Manaresi, N., Klein, C.A., Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol. Med. 6 (2014), 1371–1386.
48. De Luca, F., Rotunno, G., Salvianti, F., Galardi, F., Pestrin, M., Gabellini, S., Simi, L., Mancini, I., Vannucchi, A.M., Pazzagli, M., Di Leo, A., Pinzani, P., Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget 7 (2016), 26107–26119.
49. Bingham, C., Fernandez, S.V., Fittipaldi, P., Dempsey, P.W., Ruth, K.J., Cristofanilli, M., Katherine Alpaugh, R., Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Res. Treat. 163 (2017), 219–230.
50. Fernandez, S.V., Bingham, C., Fittipaldi, P., Austin, L., Palazzo, J., Palmer, G., Alpaugh, K., Cristofanilli, M., TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res., 16, 2014, 445.
51. Peeters, D.J., De Laere, B., Van den Eynden, G.G., Van Laere, S.J., Rothe, F., Ignatiadis, M., Sieuwerts, A.M., Lambrechts, D., Rutten, A., van Dam, P.A., Pauwels, P., Peeters, M., Vermeulen, P.B., Dirix, L.Y., Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br. J. Cancer 108 (2013), 1358–1367.
52. Pestrin, M., Salvianti, F., Galardi, F., De Luca, F., Turner, N., Malorni, L., Pazzagli, M., Di Leo, A., Pinzani, P., Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol. 9 (2015), 749–757.
53. Salvianti, F., Rotunno, G., Galardi, F., De Luca, F., Pestrin, M., Vannucchi, A.M., Di Leo, A., Pazzagli, M., Pinzani, P., Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing. Biomol. Detect. Quantif. 5 (2015), 23–29.
54. Shaw, J.A., Guttery, D.S., Hills, A., Fernandez-Garcia, D., Page, K., Rosales, B.M., Goddard, K.S., Hastings, R.K., Luo, J., Ogle, O., Woodley, L., Ali, S., Stebbing, J., Coombes, R.C., Mutation analysis of cell-free DNA and Single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin. Cancer Res. 23 (2017), 88–96.
55. Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E.M., Lax, S., Waldispuehl-Geigl, J., Mauermann, O., Lackner, C., Hofler, G., Eisner, F., Sill, H., Samonigg, H., Pantel, K., Riethdorf, S., Bauernhofer, T., Geigl, J.B., Speicher, M.R., Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 73 (2013), 2965–2975.
56. Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A.M., Mauermann, O., Izbicki, J.R., Pantel, K., Riethdorf, S., Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59 (2013), 252–260.
57. Gasch, C., Oldopp, T., Mauermann, O., Gorges, T.M., Andreas, A., Coith, C., Muller, V., Fehm, T., Janni, W., Pantel, K., Riethdorf, S., Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. Mol. Oncol. 10 (2016), 1330–1343.
58. Gasch, C., Pantel, K., Riethdorf, S., Whole genome amplification in genomic analysis of single circulating tumor cells. Methods Mol. Biol. 1347 (2015), 221–232.
59. Gorges, T.M., Kuske, A., Rock, K., Mauermann, O., Muller, V., Peine, S., Verpoort, K., Novosadova, V., Kubista, M., Riethdorf, S., Pantel, K., Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin. Chem. 62 (2016), 1504–1515.
60. Babayan, A., Alawi, M., Gormley, M., Muller, V., Wikman, H., McMullin, R.P., Smirnov, D.A., Li, W., Geffken, M., Pantel, K., Joosse, S.A., Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget 8 (2016), 56066–56080.
61. Neumann, M.H., Schneck, H., Decker, Y., Schomer, S., Franken, A., Endris, V., Pfarr, N., Weichert, W., Niederacher, D., Fehm, T., Neubauer, H., Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch(R) system and the CellCelector. Biotechnol. Prog. 33 (2017), 125–132.
62. Neves, R.P., Raba, K., Schmidt, O., Honisch, E., Meier-Stiegen, F., Behrens, B., Mohlendick, B., Fehm, T., Neubauer, H., Klein, C.A., Polzer, B., Sproll, C., Fischer, J.C., Niederacher, D., Stoecklein, N.H., Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Clin. Chem. 60 (2014), 1290–1297.
63. Riethdorf, S., Muller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., Roller, M., Huober, J., Fehm, T., Schrader, I., Hilfrich, J., Holms, F., Tesch, H., Eidtmann, H., Untch, M., von Minckwitz, G., Pantel, K., Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16 (2010), 2634–2645.
64. Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., Allred, D.C., Bartlett, J.M., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Mangu, P.B., Paik, S., Perez, E.A., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., Hayes, D.F., O. American Society of Clinical, P. College of American, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31 (2013), 3997–4013.
65. Munzone, E., Nole, F., Goldhirsch, A., Botteri, E., Esposito, A., Zorzino, L., Curigliano, G., Minchella, I., Adamoli, L., Cassatella, M.C., Casadio, C., Sandri, M.T., Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin. Breast Cancer 10 (2010), 392–397.
66. Punnoose, E.A., Atwal, S.K., Spoerke, J.M., Savage, H., Pandita, A., Yeh, R.F., Pirzkall, A., Fine, B.M., Amler, L.C., Chen, D.S., Lackner, M.R., Molecular biomarker analyses using circulating tumor cells. PLoS One, 5, 2010, e12517.
67. Pestrin, M., Bessi, S., Puglisi, F., Minisini, A.M., Masci, G., Battelli, N., Ravaioli, A., Gianni, L., Di Marsico, R., Tondini, C., Gori, S., Coombes, C.R., Stebbing, J., Biganzoli, L., Buyse, M., Di Leo, A., Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat. 134 (2012), 283–289.
68. Wallwiener, M., Hartkopf, A.D., Riethdorf, S., Nees, J., Sprick, M.R., Schonfisch, B., Taran, F.A., Heil, J., Sohn, C., Pantel, K., Trumpp, A., Schneeweiss, A., The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer, 15, 2015, 403.
69. Beije, N., Onstenk, W., Kraan, J., Sieuwerts, A.M., Hamberg, P., Dirix, L.Y., Brouwer, A., de Jongh, F.E., Jager, A., Seynaeve, C.M., Van, N.M., Foekens, J.A., Martens, J.W., Sleijfer, S., Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor. Neoplasia 18 (2016), 647–653.
70. Zhang, S., Li, L., Wang, T., Bian, L., Hu, H., Xu, C., Liu, B., Liu, Y., Cristofanilli, M., Jiang, Z., Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer, 16, 2016, 526.
71. Rink, M., Chun, F.K., Dahlem, R., Soave, A., Minner, S., Hansen, J., Stoupiec, M., Coith, C., Kluth, L.A., Ahyai, S.A., Friedrich, M.G., Shariat, S.F., Fisch, M., Pantel, K., Riethdorf, S., Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur. Urol. 61 (2012), 810–817.
72. Iwatsuki, M., Toyoshima, K., Watanabe, M., Hayashi, N., Ishimoto, T., Eto, K., Iwagami, S., Baba, Y., Yoshida, N., Hayashi, A., Ohta, Y., Baba, H., Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br. J. Cancer 109 (2013), 2829–2832.
73. Azim, H.A. Jr., Rothe, F., Aura, C.M., Bavington, M., Maetens, M., Rouas, G., Gebhart, G., Gamez, C., Eidtmann, H., Baselga, J., Piccart-Gebhart, M., Ellis, C., Vuylsteke, P., Cure, H., Domont, J., Ferro, A., Toral-Pena, J.C., de Azambuja, E., Sotiriou, C., Di Cosimo, S., Ignatiadis, M., Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. Breast 22 (2013), 1060–1065.
74. Stojadinovic, A., Mittendorf, E.A., Holmes, J.P., Amin, A., Hueman, M.T., Ponniah, S., Peoples, G.E., Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study. Ann. Surg. Oncol. 14 (2007), 3359–3368.
75. Ignatiadis, M., Rothe, F., Chaboteaux, C., Durbecq, V., Rouas, G., Criscitiello, C., Metallo, J., Kheddoumi, N., Singhal, S.K., Michiels, S., Veys, I., Rossari, J., Larsimont, D., Carly, B., Pestrin, M., Bessi, S., Buxant, F., Liebens, F., Piccart, M., Sotiriou, C., HER2-positive circulating tumor cells in breast cancer. PLoS One, 6, 2011, e15624.
76. Liu, Y., Liu, Q., Wang, T., Bian, L., Zhang, S., Hu, H., Li, S., Hu, Z., Wu, S., Liu, B., Jiang, Z., Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer, 13, 2013, 202.
77. Sieuwerts, A.M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F.E., Stouthard, J.M., Dirix, L.Y., van Dam, P.A., Van Galen, A., de Weerd, V., Kraan, J., van der Spoel, P., Ramirez-Moreno, R., van Deurzen, C.H., Smid, M., Yu, J.X., Jiang, J., Wang, Y., Gratama, J.W., Sleijfer, S., Foekens, J.A., Martens, J.W., mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res. 17 (2011), 3600–3618.
78. Li, Y., Zhang, X., Ge, S., Gao, J., Gong, J., Lu, M., Zhang, Q., Cao, Y., Wang, D.D., Lin, P.P., Shen, L., Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget 5 (2014), 6594–6602.
79. Payne, R.E., Yague, E., Slade, M.J., Apostolopoulos, C., Jiao, L.R., Ward, B., Coombes, R.C., Stebbing, J., Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10 (2009), 51–57.
80. Stebbing, J., Payne, R., Reise, J., Frampton, A.E., Avery, M., Woodley, L., Di Leo, A., Pestrin, M., Krell, J., Coombes, R.C., The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One, 8, 2013, e62543.
81. Kuboki, Y., Matsusaka, S., Minowa, S., Shibata, H., Suenaga, M., Shinozaki, E., Mizunuma, N., Ueno, M., Yamaguchi, T., Hatake, K., Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 33 (2013), 3905–3910.
82. Okegawa, T., Itaya, N., Hara, H., Tambo, M., Nutahara, K., Epidermal growth factor receptor status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with docetaxel chemotherapy. Int. J. Mol. Sci., 17, 2016 (pii: E2008).
83. Grisanti, S., Almici, C., Consoli, F., Buglione, M., Verardi, R., Bolzoni-Villaret, A., Bianchetti, A., Ciccarese, C., Mangoni, M., Ferrari, L., Biti, G., Marini, M., Ferrari, V.D., Nicolai, P., Magrini, S.M., Berruti, A., Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. PLoS One, 9, 2014, e103918.
84. Punnoose, E.A., Atwal, S., Liu, W., Raja, R., Fine, B.M., Hughes, B.G., Hicks, R.J., Hampton, G.M., Amler, L.C., Pirzkall, A., Lackner, M.R., Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18 (2012), 2391–2401.
85. Paoletti, C., Muniz, M.C., Thomas, D.G., Griffith, K.A., Kidwell, K.M., Tokudome, N., Brown, M.E., Aung, K., Miller, M.C., Blossom, D.L., Schott, A.F., Henry, N.L., Rae, J.M., Connelly, M.C., Chianese, D.A., Hayes, D.F., Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin. Cancer Res. 21 (2015), 2487–2498.
86. Paoletti, C., Larios, J.M., Muniz, M.C., Aung, K., Cannell, E.M., Darga, E.P., Kidwell, K.M., Thomas, D.G., Tokudome, N., Brown, M.E., Connelly, M.C., Chianese, D.A., Schott, A.F., Henry, N.L., Rae, J.M., Hayes, D.F., Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Mol. Oncol. 10 (2016), 1078–1085.
87. de Bono, J.S., Attard, G., Adjei, A., Pollak, M.N., Fong, P.C., Haluska, P., Roberts, L., Melvin, C., Repollet, M., Chianese, D., Connely, M., Terstappen, L.W., Gualberto, A., Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 13 (2007), 3611–3616.
88. Childs, A., Vesely, C., Ensell, L., Lowe, H., Luong, T.V., Caplin, M.E., Toumpanakis, C., Thirlwell, C., Hartley, J.A., Meyer, T., Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br. J. Cancer 115 (2016), 1540–1547.
89. Lindsay, C.R., Le Moulec, S., Billiot, F., Loriot, Y., Ngo-Camus, M., Vielh, P., Fizazi, K., Massard, C., Farace, F., Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer, 16, 2016, 168.
90. Armstrong, A.J., Marengo, M.S., Oltean, S., Kemeny, G., Bitting, R.L., Turnbull, J.D., Herold, C.I., Marcom, P.K., George, D.J., Garcia-Blanco, M.A., Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 9 (2011), 997–1007.
91. Lowes, L.E., Hedley, B.D., Keeney, M., Allan, A.L., User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch(R) system. Cytometry A 81 (2012), 983–995.
92. Rossi, E., Basso, U., Celadin, R., Zilio, F., Pucciarelli, S., Aieta, M., Barile, C., Sava, T., Bonciarelli, G., Tumolo, S., Ghiotto, C., Magro, C., Jirillo, A., Indraccolo, S., Amadori, A., Zamarchi, R., M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin. Cancer Res. 16 (2010), 5233–5243.
93. Hou, J.M., Greystoke, A., Lancashire, L., Cummings, J., Ward, T., Board, R., Amir, E., Hughes, S., Krebs, M., Hughes, A., Ranson, M., Lorigan, P., Dive, C., Blackhall, F.H., Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 175 (2009), 808–816.
94. Smerage, J.B., Budd, G.T., Doyle, G.V., Brown, M., Paoletti, C., Muniz, M., Miller, M.C., Repollet, M.I., Chianese, D.A., Connelly, M.C., Terstappen, L.W., Hayes, D.F., Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol. Oncol. 7 (2013), 680–692.
95. Dotan, E., Alpaugh, R.K., Ruth, K., Negin, B.P., Denlinger, C.S., Hall, M.J., Astsaturov, I., McAleer, C., Fittipaldi, P., Thrash-Bingham, C., Meropol, N.J., Cohen, S.J., Prognostic significance of MUC-1 in circulating tumor cells in patients with metastatic pancreatic adenocarcinoma. Pancreas 45 (2016), 1131–1135.
96. Pal, S.K., He, M., Wilson, T., Liu, X., Zhang, K., Carmichael, C., Torres, A., Hernandez, S., Lau, C., Agarwal, N., Kawachi, M., Yen, Y., Jones, J.O., Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin. Genitourin. Cancer 13 (2015), 130–136.
97. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A.J., Rogers, A.M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B.E., Cantley, L.C., Janne, P.A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
98. Matthew, E.M., Zhou, L., Yang, Z., Dicker, D.T., Holder, S.L., Lim, B., Harouaka, R., Zheng, S.Y., Drabick, J.J., Lamparella, N.E., Truica, C.I., El-Deiry, W.S., A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget 7 (2016), 3662–3676.
99. Mazel, M., Jacot, W., Pantel, K., Bartkowiak, K., Topart, D., Cayrefourcq, L., Rossille, D., Maudelonde, T., Fest, T., Alix-Panabieres, C., Frequent expression of PD-L1 on circulating breast cancer cells. Mol. Oncol. 9 (2015), 1773–1782.
100. Nicolazzo, C., Raimondi, C., Mancini, M., Caponnetto, S., Gradilone, A., Gandini, O., Mastromartino, M., Del Bene, G., Prete, A., Longo, F., Cortesi, E., Gazzaniga, P., Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep., 6, 2016, 31726.
101. Wang, L.H., Pfister, T.D., Parchment, R.E., Kummar, S., Rubinstein, L., Evrard, Y.A., Gutierrez, M.E., Murgo, A.J., Tomaszewski, J.E., Doroshow, J.H., Kinders, R.J., Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin. Cancer Res. 16 (2010), 1073–1084.
102. Gorges, T.M., Riethdorf, S., von Ahsen, O., Nastal, Y.P., Rock, K., Boede, M., Peine, S., Kuske, A., Schmid, E., Kneip, C., Konig, F., Rudolph, M., Pantel, K., Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget 7 (2016), 34930–34941.
103. Kershaw, S., Cummings, J., Morris, K., Tugwood, J., Dive, C., Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. BMC Cancer, 15, 2015, 387.
104. Khan, M.S., Tsigani, T., Rashid, M., Rabouhans, J.S., Yu, D., Luong, T.V., Caplin, M., Meyer, T., Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin. Cancer Res. 17 (2011), 337–345.
105. He, X., Liao, Y., Lu, W., Xu, G., Tong, H., Ke, J., Wan, X., Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma. Tumour Biol. 37 (2016), 9951–9958.
106. Lemech, C.R., Ensell, L., Paterson, J.C., Eminowicz, G., Lowe, H., Arora, R., Arkenau, H.T., Widschwendter, M., MacDonald, N., Olaitan, A., Mould, T., Meyer, T., Hartley, J., Mitra, A., Ledermann, J.A., McCormack, M., Kristeleit, R.S., Enumeration and molecular characterisation of circulating tumour cells in endometrial cancer. Oncology 91 (2016), 48–54.
107. Marchetti, A., Del Grammastro, M., Felicioni, L., Malatesta, S., Filice, G., Centi, I., De Pas, T., Santoro, A., Chella, A., Brandes, A.A., Venturino, P., Cuccurullo, F., Crino, L., Buttitta, F., Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One, 9, 2014, e103883.
108. Schneck, H., Blassl, C., Meier-Stiegen, F., Neves, R.P., Janni, W., Fehm, T., Neubauer, H., Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol. 7 (2013), 976–986.
109. Leversha, M.A., Han, J., Asgari, Z., Danila, D.C., Lin, O., Gonzalez-Espinoza, R., Anand, A., Lilja, H., Heller, G., Fleisher, M., Scher, H.I., Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res. 15 (2009), 2091–2097.
110. Attard, G., Swennenhuis, J.F., Olmos, D., Reid, A.H., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., Oommen, N.B., Hawche, G., Jameson, C., Thompson, E., Sipkema, R., Carden, C.P., Parker, C., Dearnaley, D., Kaye, S.B., Cooper, C.S., Molina, A., Cox, M.E., Terstappen, L.W., de Bono, J.S., Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69 (2009), 2912–2918.
111. Swennenhuis, J.F., Terstappen, L., Sample preparation methods following CellSearch approach compatible of single-cell whole-genome amplification: an overview. Methods Mol. Biol. 1347 (2015), 57–67.
112. Pixberg, C.F., Raba, K., Muller, F., Behrens, B., Honisch, E., Niederacher, D., Neubauer, H., Fehm, T., Goering, W., Schulz, W.A., Flohr, P., Boysen, G., Lambros, M., De Bono, J.S., Knoefel, W.T., Sproll, C., Stoecklein, N.H., Neves, R.P., Analysis of DNA methylation in single circulating tumor cells. Oncogene 36 (2017), 3223–3231.
113. Rossi, E., Rugge, M., Facchinetti, A., Pizzi, M., Nardo, G., Barbieri, V., Manicone, M., De Faveri, S., Chiara Scaini, M., Basso, U., Amadori, A., Zamarchi, R., Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience 1 (2014), 49–56.
114. Smirnov, D.A., Zweitzig, D.R., Foulk, B.W., Miller, M.C., Doyle, G.V., Pienta, K.J., Meropol, N.J., Weiner, L.M., Cohen, S.J., Moreno, J.G., Connelly, M.C., Terstappen, L.W., O'Hara, S.M., Global gene expression profiling of circulating tumor cells. Cancer Res. 65 (2005), 4993–4997.
115. Sieuwerts, A.M., Kraan, J., Bolt-de Vries, J., van der Spoel, P., Mostert, B., Martens, J.W., Gratama, J.W., Sleijfer, S., Foekens, J.A., Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res. Treat. 118 (2009), 455–468.
116. Onstenk, W., Sieuwerts, A.M., Weekhout, M., Mostert, B., Reijm, E.A., van Deurzen, C.H., Bolt-de Vries, J.B., Peeters, D.J., Hamberg, P., Seynaeve, C., Jager, A., de Jongh, F.E., Smid, M., Dirix, L.Y., Kehrer, D.F., van Galen, A., Ramirez-Moreno, R., Kraan, J., Van, M., Gratama, J.W., Martens, J.W., Foekens, J.A., Sleijfer, S., Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Lett. 362 (2015), 36–44.
117. Onstenk, W., Sieuwerts, A.M., Mostert, B., Lalmahomed, Z., Bolt-de Vries, J.B., van Galen, A., Smid, M., Kraan, J., Van, M., de Weerd, V., Ramirez-Moreno, R., Biermann, K., Verhoef, C., Grunhagen, D.J., JN, I.J., Gratama, J.W., Martens, J.W., Foekens, J.A., Sleijfer, S., Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget 7 (2016), 59058–59069.
118. Mostert, B., Sieuwerts, A.M., Bolt-de Vries, J., Kraan, J., Lalmahomed, Z., van Galen, A., van der Spoel, P., de Weerd, V., Ramirez-Moreno, R., Smid, M., Verhoef, C., JN, I.J., Gratama, J.W., Sleijfer, S., Foekens, J.A., Martens, J.W., mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol. Oncol. 9 (2015), 920–932.
119. Antonarakis, E.S., Nakazawa, M., Luo, J., Resistance to androgen-pathway drugs in prostate cancer. N. Engl. J. Med. 371 (2014), 1028–1038.
120. Antonarakis, E.S., Lu, C., Luber, B., Wang, H., Chen, Y., Zhu, Y., Silberstein, J.L., Taylor, M.N., Maughan, B.L., Denmeade, S.R., Pienta, K.J., Paller, C.J., Carducci, M.A., Eisenberger, M.A., Luo, J., Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J. Clin. Oncol. 35 (2017), 2149–2156.
121. Bulfoni, M., Gerratana, L., Del Ben, F., Marzinotto, S., Sorrentino, M., Turetta, M., Scoles, G., Toffoletto, B., Isola, M., Beltrami, C.A., Di Loreto, C., Beltrami, A.P., Puglisi, F., Cesselli, D., In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res., 18, 2016, 30.
122. Gasch, C., Plummer, P.N., Jovanovic, L., McInnes, L.M., Wescott, D., Saunders, C.M., Schneeweiss, A., Wallwiener, M., Nelson, C., Spring, K.J., Riethdorf, S., Thompson, E.W., Pantel, K., Mellick, A.S., Heterogeneity of miR-10b expression in circulating tumor cells. Sci. Rep., 5, 2015, 15980.
123. Le Rhun, E., Massin, F., Tu, Q., Bonneterre, J., Bittencourt Mde, C., Faure, G.C., Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin. Pathol., 12, 2012, 21.
124. Le Rhun, E., Tu, Q., De Carvalho Bittencourt, M., Farre, I., Mortier, L., Cai, H., Kohler, C., Faure, G.C., Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med. Oncol., 30, 2013, 538.
125. Patel, A.S., Allen, J.E., Dicker, D.T., Peters, K.L., Sheehan, J.M., Glantz, M.J., El-Deiry, W.S., Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2 (2011), 752–760.
126. Tu, Q., Wu, X., Le Rhun, E., Blonski, M., Wittwer, B., Taillandier, L., De Carvalho Bittencourt, M., Faure, G.C., CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer 90 (2015), 352–357.
127. Tu, Q., Bittencourt Mde, C., Cai, H., Bastien, C., Lemarie-Delaunay, C., Bene, M.C., Faure, G.C., Case report: detection and quantification of tumor cells in peripheral blood and ascitic fluid from a metastatic esophageal cancer patient using the CellSearch ((R)) technology. F1000Res, 3, 2014, 12.
128. Mastronicola, R., Berteau, C., Tu, Q., Cortese, S., Guillet, J., Phulpin, B., Gangloff, P., Bezdetnaya, L., Merlin, J.L., Faure, G., Dolivet, G., Detection of disseminated tumor cells in aspirative drains after neck dissection. Eur. Arch. Otorhinolaryngol. 273 (2016), 465–469.
129. Fischer, J.C., Niederacher, D., Topp, S.A., Honisch, E., Schumacher, S., Schmitz, N., Zacarias Fohrding, L., Vay, C., Hoffmann, I., Kasprowicz, N.S., Hepp, P.G., Mohrmann, S., Nitz, U., Stresemann, A., Krahn, T., Henze, T., Griebsch, E., Raba, K., Rox, J.M., Wenzel, F., Sproll, C., Janni, W., Fehm, T., Klein, C.A., Knoefel, W.T., Stoecklein, N.H., Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 16580–16585.
130. Wind, J., Tuynman, J.B., Tibbe, A.G., Swennenhuis, J.F., Richel, D.J., van Berge Henegouwen, M.I., Bemelman, W.A., Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur. J. Surg. Oncol. 35 (2009), 942–950.
131. Deneve, E., Riethdorf, S., Ramos, J., Nocca, D., Coffy, A., Daures, J.P., Maudelonde, T., Fabre, J.M., Pantel, K., Alix-Panabieres, C., Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin. Chem. 59 (2013), 1384–1392.
132. Rahbari, N.N., Bork, U., Kircher, A., Nimitz, T., Scholch, S., Kahlert, C., Schmidt, T., Steinert, G., Ulrich, A.B., Reissfelder, C., Buchler, M.W., Koch, M., Weitz, J., Compartmental differences of circulating tumor cells in colorectal cancer. Ann. Surg. Oncol. 19 (2012), 2195–2202.
133. Catenacci, D.V., Chapman, C.G., Xu, P., Koons, A., Konda, V.J., Siddiqui, U.D., Waxman, I., Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology 149 (2015), 1794–1803 e1794.
134. Bissolati, M., Sandri, M.T., Burtulo, G., Zorzino, L., Balzano, G., Braga, M., Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumour Biol. 36 (2015), 991–996.
135. Crosbie, P.A., Shah, R., Krysiak, P., Zhou, C., Morris, K., Tugwood, J., Booton, R., Blackhall, F., Dive, C., Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC. J. Thorac. Oncol. 11 (2016), 1793–1797.
136. Connor, A.A., McNamara, K., Al-Sukhni, E., Diskin, J., Chan, D., Ash, C., Lowes, L.E., Allan, A.L., Zogopoulos, G., Moulton, C.A., Gallinger, S., Central, but not peripheral, circulating tumor cells are prognostic in patients undergoing resection of colorectal cancer liver metastases. Ann. Surg. Oncol. 23 (2016), 2168–2175.
137. Engilbertsson, H., Aaltonen, K.E., Bjornsson, S., Kristmundsson, T., Patschan, O., Ryden, L., Gudjonsson, S., Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J. Urol. 193 (2015), 53–57.
138. Blaschke, S., Koenig, F., Schostak, M., Hematogenous tumor cell spread following standard transurethral resection of bladder carcinoma. Eur. Urol. 70 (2016), 544–545.
139. Tsumura, H., Satoh, T., Ishiyama, H., Tabata, K.I., Takenaka, K., Sekiguchi, A., Nakamura, M., Kitano, M., Hayakawa, K., Iwamura, M., Perioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancer. Int. J. Mol. Sci., 18, 2017 (pii: E128).
140. Hashimoto, M., Tanaka, F., Yoneda, K., Takuwa, T., Matsumoto, S., Okumura, Y., Kondo, N., Tsubota, N., Tsujimura, T., Tabata, C., Nakano, T., Hasegawa, S., Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact. Cardiovasc. Thorac. Surg. 18 (2014), 775–783.
141. Sawabata, N., Okumura, M., Utsumi, T., Inoue, M., Shiono, H., Minami, M., Nishida, T., Sawa, Y., Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen. Thorac. Cardiovasc. Surg. 55 (2007), 189–192.
142. Fornvik, D., Andersson, I., Dustler, M., Ehrnstrom, R., Ryden, L., Tingberg, A., Zackrisson, S., Aaltonen, K., No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression. Breast Cancer Res. Treat. 141 (2013), 187–195.
143. Cristofanilli, M., Hayes, D.F., Budd, G.T., Ellis, M.J., Stopeck, A., Reuben, J.M., Doyle, G.V., Matera, J., Allard, W.J., Miller, M.C., Fritsche, H.A., Hortobagyi, G.N., Terstappen, L.W., Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23 (2005), 1420–1430.
144. Dawood, S., Broglio, K., Valero, V., Reuben, J., Handy, B., Islam, R., Jackson, S., Hortobagyi, G.N., Fritsche, H., Cristofanilli, M., Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer 113 (2008), 2422–2430.
145. Hayes, D.F., Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Miller, M.C., Matera, J., Allard, W.J., Doyle, G.V., Terstappen, L.W., Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12 (2006), 4218–4224.
146. Nole, F., Munzone, E., Zorzino, L., Minchella, I., Salvatici, M., Botteri, E., Medici, M., Verri, E., Adamoli, L., Rotmensz, N., Goldhirsch, A., Sandri, M.T., Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann. Oncol. 19 (2008), 891–897.
147. Paoletti, C., Li, Y., Muniz, M.C., Kidwell, K.M., Aung, K., Thomas, D.G., Brown, M.E., Abramson, V.G., Irvin, W.J. Jr., Lin, N.U., Liu, M.C., Nanda, R., Nangia, J.R., Storniolo, A.M., Traina, T.A., Vaklavas, C., Van Poznak, C.H., Wolff, A.C., Forero-Torres, A., Hayes, D.F., C. Translational Breast Cancer Research, Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin. Cancer Res. 21 (2015), 2771–2779.
148. Yan, W.T., Cui, X., Chen, Q., Li, Y.F., Cui, Y.H., Wang, Y., Jiang, J., Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci. Rep., 7, 2017, 43464.
149. Giuliano, M., Giordano, A., Jackson, S., Hess, K.R., De Giorgi, U., Mego, M., Handy, B.C., Ueno, N.T., Alvarez, R.H., De Laurentiis, M., De Placido, S., Valero, V., Hortobagyi, G.N., Reuben, J.M., Cristofanilli, M., Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res., 13, 2011, R67.
150. Liu, M.C., Shields, P.G., Warren, R.D., Cohen, P., Wilkinson, M., Ottaviano, Y.L., Rao, S.B., Eng-Wong, J., Seillier-Moiseiwitsch, F., Noone, A.M., Isaacs, C., Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27 (2009), 5153–5159.
151. Nakamura, S., Yagata, H., Ohno, S., Yamaguchi, H., Iwata, H., Tsunoda, N., Ito, Y., Tokudome, N., Toi, M., Kuroi, K., Suzuki, E., Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 17 (2010), 199–204.
152. Hartkopf, A.D., Wagner, P., Wallwiener, D., Fehm, T., Rothmund, R., Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res. 31 (2011), 979–984.
153. Budd, G.T., Cristofanilli, M., Ellis, M.J., Stopeck, A., Borden, E., Miller, M.C., Matera, J., Repollet, M., Doyle, G.V., Terstappen, L.W., Hayes, D.F., Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12 (2006), 6403–6409.
154. Tokudome, N., Ito, Y., Takahashi, S., Kobayashi, K., Taira, S., Tsutsumi, C., Oto, M., Oba, M., Inoue, K., Kuwayama, A., Masumura, K., Nakayama, Y., Watanabe, C., Hatake, K., Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Breast Cancer 18 (2011), 195–202.
155. De Giorgi, U., Valero, V., Rohren, E., Dawood, S., Ueno, N.T., Miller, M.C., Doyle, G.V., Jackson, S., Andreopoulou, E., Handy, B.C., Reuben, J.M., Fritsche, H.A., Macapinlac, H.A., Hortobagyi, G.N., Cristofanilli, M., Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J. Clin. Oncol. 27 (2009), 3303–3311.
156. Mego, M., De Giorgi, U., Broglio, K., Dawood, S., Valero, V., Andreopoulou, E., Handy, B., Reuben, J.M., Cristofanilli, M., Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br. J. Cancer 101 (2009), 1813–1816.
157. Mego, M., Zuo, Z., Gao, H., Cohen, E.N., Giordano, A., Tin, S., Anfossi, S., Jackson, S., Woodward, W., Ueno, N.T., Valero, V., Alvarez, R.H., Hortobagyi, G.N., Khoury, J.D., Cristofanilli, M., Reuben, J.M., Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb. Haemost. 113 (2015), 593–598.
158. Mego, M., De Giorgi, U., Hsu, L., Ueno, N.T., Valero, V., Jackson, S., Andreopoulou, E., Kau, S.W., Reuben, J.M., Cristofanilli, M., Circulating tumor cells in metastatic inflammatory breast cancer. Ann. Oncol. 20 (2009), 1824–1828.
159. Mego, M., Giordano, A., De Giorgi, U., Masuda, H., Hsu, L., Giuliano, M., Fouad, T.M., Dawood, S., Ueno, N.T., Valero, V., Andreopoulou, E., Alvarez, R.H., Woodward, W.A., Hortobagyi, G.N., Cristofanilli, M., Reuben, J.M., Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res., 17, 2015, 2.
160. Mego, M., Gao, H., Cohen, E.N., Anfossi, S., Giordano, A., Tin, S., Fouad, T.M., De Giorgi, U., Giuliano, M., Woodward, W.A., Alvarez, R.H., Valero, V., Ueno, N.T., Hortobagyi, G.N., Cristofanilli, M., Reuben, J.M., Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget 8 (2017), 35656–35668.
161. Mego, M., Gao, H., Cohen, E.N., Anfossi, S., Giordano, A., Sanda, T., Fouad, T.M., De Giorgi, U., Giuliano, M., Woodward, W.A., Alvarez, R.H., Valero, V., Ueno, N.T., Hortobagyi, G.N., Cristofanilli, M., Reuben, J.M., Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. J. Cancer 7 (2016), 1095–1104.
162. Santos, M.F., Mannam, V.K., Craft, B.S., Puneky, L.V., Sheehan, N.T., Lewis, R.E., Cruse, J.M., Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. Exp. Mol. Pathol. 96 (2014), 367–374.
163. Zhang, L., Riethdorf, S., Wu, G., Wang, T., Yang, K., Peng, G., Liu, J., Pantel, K., Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 18 (2012), 5701–5710.
164. Andreopoulou, E., Cristofanilli, M., Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert. Rev. Anticancer. Ther. 10 (2010), 171–177.
165. Armakolas, A., Panteleakou, Z., Nezos, A., Tsouma, A., Skondra, M., Lembessis, P., Pissimissis, N., Koutsilieris, M., Detection of the circulating tumor cells in cancer patients. Future Oncol. 6 (2010), 1849–1856.
166. Hayes, D.F., Smerage, J.B., Circulating tumor cells. Prog. Mol. Biol. Transl. Sci. 95 (2010), 95–112.
167. Mego, M., Mani, S.A., Cristofanilli, M., Molecular mechanisms of metastasis in breast cancer–clinical applications. Nat. Rev. Clin. Oncol. 7 (2010), 693–701.
168. Swaby, R.F., Cristofanilli, M., Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med., 9, 2011, 43.
169. Bidard, F.C., Peeters, D.J., Fehm, T., Nole, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J.A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A.F., De Mattos-Arruda, L., Ignatiadis, M., Lebofsky, R., van Laere, S.J., Meier-Stiegen, F., Sandri, M.T., Vidal-Martinez, J., Politaki, E., Consoli, F., Bottini, A., Diaz-Rubio, E., Krell, J., Dawson, S.J., Raimondi, C., Rutten, A., Janni, W., Munzone, E., Caranana, V., Agelaki, S., Almici, C., Dirix, L., Solomayer, E.F., Zorzino, L., Johannes, H., Reis-Filho, J.S., Pantel, K., Pierga, J.Y., Michiels, S., Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15 (2014), 406–414.
170. Lv, Q., Gong, L., Zhang, T., Ye, J., Chai, L., Ni, C., Mao, Y., Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. Clin. Transl. Oncol. 18 (2016), 322–330.
171. Smerage, J.B., Barlow, W.E., Hortobagyi, G.N., Winer, E.P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A.F., O'Rourke, M.A., Lew, D.L., Doyle, G.V., Gralow, J.R., Livingston, R.B., Hayes, D.F., Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 32 (2014), 3483–3489.
172. Giordano, A., Egleston, B.L., Hajage, D., Bland, J., Hortobagyi, G.N., Reuben, J.M., Pierga, J.Y., Cristofanilli, M., Bidard, F.C., Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin. Cancer Res. 19 (2013), 1596–1602.
173. Mego, M., De Giorgi, U., Dawood, S., Wang, X., Valero, V., Andreopoulou, E., Handy, B., Ueno, N.T., Reuben, J.M., Cristofanilli, M., Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int. J. Cancer 129 (2011), 417–423.
174. Zhang, L., Ridgway, L.D., Wetzel, M.D., Ngo, J., Yin, W., Kumar, D., Goodman, J.C., Groves, M.D., Marchetti, D., The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med., 5, 2013, 180ra148.
175. Thiery, J.P., Lim, C.T., Tumor dissemination: an EMT affair. Cancer Cell 23 (2013), 272–273.
176. Mooney, S.M., Talebian, V., Jolly, M.K., Jia, D., Gromala, M., Levine, H., McConkey, B.J., The GRHL2/ZEB feedback loop-a key axis in the regulation of EMT in breast cancer. J. Cell. Biochem. 118 (2017), 2559–2570.
177. Pattabiraman, D.R., Weinberg, R.A., Targeting the epithelial-to-mesenchymal transition: the case for differentiation-based therapy. Cold Spring Harb. Symp. Quant. Biol. 81 (2016), 11–19.
178. Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., Kasimir-Bauer, S., Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res., 11, 2009, R46.
179. Raimondi, C., Gradilone, A., Naso, G., Vincenzi, B., Petracca, A., Nicolazzo, C., Palazzo, A., Saltarelli, R., Spremberg, F., Cortesi, E., Gazzaniga, P., Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 130 (2011), 449–455.
180. Giordano, A., Gao, H., Anfossi, S., Cohen, E., Mego, M., Lee, B.N., Tin, S., De Laurentiis, M., Parker, C.A., Alvarez, R.H., Valero, V., Ueno, N.T., De Placido, S., Mani, S.A., Esteva, F.J., Cristofanilli, M., Reuben, J.M., Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol. Cancer Ther. 11 (2012), 2526–2534.
181. Alix-Panabieres, C., Mader, S., Pantel, K., Epithelial-mesenchymal plasticity in circulating tumor cells. J. Mol. Med. (Berl.) 95 (2017), 133–142.
182. Gradilone, A., Naso, G., Raimondi, C., Cortesi, E., Gandini, O., Vincenzi, B., Saltarelli, R., Chiapparino, E., Spremberg, F., Cristofanilli, M., Frati, L., Agliano, A.M., Gazzaniga, P., Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann. Oncol. 22 (2011), 86–92.
183. Schneck, H., Gierke, B., Uppenkamp, F., Behrens, B., Niederacher, D., Stoecklein, N.H., Templin, M.F., Pawlak, M., Fehm, T., Neubauer, H., Disseminated cancer cell network, EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer. PLoS One, 10, 2015, e0144535.
184. Mego, M., Cierna, Z., Janega, P., Karaba, M., Minarik, G., Benca, J., Sedlackova, T., Sieberova, G., Gronesova, P., Manasova, D., Pindak, D., Sufliarsky, J., Danihel, L., Reuben, J.M., Mardiak, J., Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer. BMC Cancer, 15, 2015, 533.
185. Guan, X., Ma, F., Liu, S., Wu, S., Xiao, R., Yuan, L., Sun, X., Yi, Z., Yang, H., Xu, B., Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Oncotarget 7 (2016), 65993–66002.
186. Bredemeier, M., Edimiris, P., Tewes, M., Mach, P., Aktas, B., Schellbach, D., Wagner, J., Kimmig, R., Kasimir-Bauer, S., Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget 7 (2016), 41677–41690.
187. Hensler, M., Vancurova, I., Becht, E., Palata, O., Strnad, P., Tesarova, P., Cabinakova, M., Svec, D., Kubista, M., Bartunkova, J., Spisek, R., Sojka, L., Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. Oncoimmunology, 5, 2016, e1102827.
188. Munzone, E., Botteri, E., Sandri, M.T., Esposito, A., Adamoli, L., Zorzino, L., Sciandivasci, A., Cassatella, M.C., Rotmensz, N., Aurilio, G., Curigliano, G., Goldhirsch, A., Nole, F., Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin. Breast Cancer 12 (2012), 340–346.
189. Giordano, A., Giuliano, M., De Laurentiis, M., Arpino, G., Jackson, S., Handy, B.C., Ueno, N.T., Andreopoulou, E., Alvarez, R.H., Valero, V., De Placido, S., Hortobagyi, G.N., Reuben, J.M., Cristofanilli, M., Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. 23 (2012), 1144–1150.
190. Lu, Y.J., Wang, P., Wang, X., Peng, J., Zhu, Y.W., Shen, N., The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis. Oncotarget 7 (2016), 37361–37369.
191. Wallwiener, M., Hartkopf, A.D., Baccelli, I., Riethdorf, S., Schott, S., Pantel, K., Marme, F., Sohn, C., Trumpp, A., Rack, B., Aktas, B., Solomayer, E.F., Muller, V., Janni, W., Schneeweiss, A., Fehm, T.N., The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res. Treat. 137 (2013), 503–510.
192. Janni, W.J., Rack, B., Terstappen, L.W., Pierga, J.Y., Taran, F.A., Fehm, T., Hall, C., de Groot, M.R., Bidard, F.C., Friedl, T.W., Fasching, P.A., Brucker, S.Y., Pantel, K., Lucci, A., Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin. Cancer Res. 22 (2016), 2583–2593.
193. Sandri, M.T., Zorzino, L., Cassatella, M.C., Bassi, F., Luini, A., Casadio, C., Botteri, E., Rotmensz, N., Adamoli, L., Nole, F., Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann. Surg. Oncol. 17 (2010), 1539–1545.
194. Krishnamurthy, S., Cristofanilli, M., Singh, B., Reuben, J., Gao, H., Cohen, E.N., Andreopoulou, E., Hall, C.S., Lodhi, A., Jackson, S., Lucci, A., Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116 (2010), 3330–3337.
195. Lucci, A., Hall, C.S., Lodhi, A.K., Bhattacharyya, A., Anderson, A.E., Xiao, L., Bedrosian, I., Kuerer, H.M., Krishnamurthy, S., Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 13 (2012), 688–695.
196. Hall, C.S., Karhade, M.G., Bowman Bauldry, J.B., Valad, L.M., Kuerer, H.M., DeSnyder, S.M., Lucci, A., Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J. Am. Coll. Surg. 223 (2016), 20–29.
197. Hartkopf, A.D., Wallwiener, M., Hahn, M., Fehm, T.N., Brucker, S.Y., Taran, F.A., Simultaneous detection of disseminated and circulating tumor cells in primary breast cancer patients. Cancer Res. Treat. 48 (2016), 115–124.
198. Bidard, F.C., Mathiot, C., Delaloge, S., Brain, E., Giachetti, S., de Cremoux, P., Marty, M., Pierga, J.Y., Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 21 (2010), 729–733.
199. Reyal, F., Valet, F., de Cremoux, P., Mathiot, C., Decraene, C., Asselain, B., Brain, E., Delaloge, S., Giacchetti, S., Marty, M., Pierga, J.Y., Bidard, F.C., Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann. Oncol. 22 (2011), 1458–1459.
200. Mego, M., Mani, S.A., Lee, B.N., Li, C., Evans, K.W., Cohen, E.N., Gao, H., Jackson, S.A., Giordano, A., Hortobagyi, G.N., Cristofanilli, M., Lucci, A., Reuben, J.M., Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int. J. Cancer 130 (2012), 808–816.
201. Pierga, J.Y., Bidard, F.C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., Marty, M., Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 14 (2008), 7004–7010.
202. Bidard, F.C., Belin, L., Delaloge, S., Lerebours, F., Ngo, C., Reyal, F., Alran, S., Giacchetti, S., Marty, M., Lebofsky, R., Pierga, J.Y., Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int. J. Breast Cancer, 2013, 2013, 130470.
203. Pantel, K., Alix-Panabieres, C., Riethdorf, S., Cancer micrometastases. Nat. Rev. Clin. Oncol. 6 (2009), 339–351.
204. Pestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Biagioni, C., Cappadona, S., Biganzoli, L., Giannini, A., Di Leo, A., Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 118 (2009), 523–530.
205. Somlo, G., Lau, S.K., Frankel, P., Hsieh, H.B., Liu, X., Yang, L., Krivacic, R., Bruce, R.H., Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 128 (2011), 155–163.
206. Aaltonen, K.E., Novosadova, V., Bendahl, P.O., Graffman, C., Larsson, A.M., Ryden, L., Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget 8 (2017), 45544–45565.
207. Wang, C.H., Chang, C.J., Yeh, K.Y., Chang, P.H., Huang, J.S., The prognostic value of HER2-positive circulating tumor cells in breast cancer patients: a systematic review and meta-analysis. Clin. Breast Cancer 17 (2017), 341–349.
208. Bidard, F.C., Fehm, T., Ignatiadis, M., Smerage, J.B., Alix-Panabieres, C., Janni, W., Messina, C., Paoletti, C., Muller, V., Hayes, D.F., Piccart, M., Pierga, J.Y., Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 32 (2013), 179–188.
209. Scher, H.I., Jia, X., de Bono, J.S., Fleisher, M., Pienta, K.J., Raghavan, D., Heller, G., Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10 (2009), 233–239.
210. Goodman, O.B. Jr., Fink, L.M., Symanowski, J.T., Wong, B., Grobaski, B., Pomerantz, D., Ma, Y., Ward, D.C., Vogelzang, N.J., Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol. Biomark. Prev. 18 (2009), 1904–1913.
211. Okegawa, T., Itaya, N., Hara, H., Tambo, M., Nutahara, K., Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res. 34 (2014), 6705–6710.
212. Vogelzang, N.J., Fizazi, K., Burke, J.M., De Wit, R., Bellmunt, J., Hutson, T.E., Crane, E., Berry, W.R., Doner, K., Hainsworth, J.D., Wiechno, P.J., Liu, K., Waldman, M.F., Gandhi, A., Barton, D., Jungnelius, U., Fandi, A., Sternberg, C.N., Petrylak, D.P., Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer. Eur. Urol. 71 (2017), 168–171.
213. Goldkorn, A., Ely, B., Quinn, D.I., Tangen, C.M., Fink, L.M., Xu, T., Twardowski, P., Van Veldhuizen, P.J., Agarwal, N., Carducci, M.A., Monk, J.P. 3rd, Datar, R.H., Garzotto, M., Mack, P.C., Lara, P. Jr., Higano, C.S., Hussain, M., Thompson, I.M. Jr., Cote, R.J., Vogelzang, N.J., Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 32 (2014), 1136–1142.
214. Danila, D.C., Heller, G., Gignac, G.A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., Scher, H.I., Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13 (2007), 7053–7058.
215. Aragon-Ching, J.B., Jain, L., Gulley, J.L., Arlen, P.M., Wright, J.J., Steinberg, S.M., Draper, D., Venitz, J., Jones, E., Chen, C.C., Figg, W.D., Dahut, W.L., Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 103 (2009), 1636–1640.
216. Dahut, W.L., Scripture, C., Posadas, E., Jain, L., Gulley, J.L., Arlen, P.M., Wright, J.J., Yu, Y., Cao, L., Steinberg, S.M., Aragon-Ching, J.B., Venitz, J., Jones, E., Chen, C.C., Figg, W.D., A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 14 (2008), 209–214.
217. Scher, H.I., Morris, M.J., Stadler, W.M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E.S., Beer, T.M., Carducci, M.A., Chi, K.N., Corn, P.G., de Bono, J.S., Dreicer, R., George, D.J., Heath, E.I., Hussain, M., Kelly, W.K., Liu, G., Logothetis, C., Nanus, D., Stein, M.N., Rathkopf, D.E., Slovin, S.F., Ryan, C.J., Sartor, O., Small, E.J., Smith, M.R., Sternberg, C.N., Taplin, M.E., Wilding, G., Nelson, P.S., Schwartz, L.H., Halabi, S., Kantoff, P.W., Armstrong, A.J., G. Prostate Cancer Clinical Trials Working, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J. Clin. Oncol. 34 (2016), 1402–1418.
218. Scher, H.I., Heller, G., Molina, A., Attard, G., Danila, D.C., Jia, X., Peng, W., Sandhu, S.K., Olmos, D., Riisnaes, R., McCormack, R., Burzykowski, T., Kheoh, T., Fleisher, M., Buyse, M., de Bono, J.S., Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 33 (2015), 1348–1355.
219. Prentice, R.L., Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8 (1989), 431–440.
220. Heller, G., Fizazi, K., McCormack, R., Molina, A., MacLean, D., Webb, I.J., Saad, F., de Bono, J.S., Scher, H.I., The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population. Clin. Cancer Res. 23 (2017), 1967–1973.
221. Thalgott, M., Rack, B., Horn, T., Heck, M.M., Eiber, M., Kubler, H., Retz, M., Gschwend, J.E., Andergassen, U., Nawroth, R., Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy. Anticancer Res. 35 (2015), 5679–5685.
222. Meyer, C.P., Pantel, K., Tennstedt, P., Stroelin, P., Schlomm, T., Heinzer, H., Riethdorf, S., Steuber, T., Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol. Oncol. 34:235 (2016), e211–236.
223. Loh, J., Jovanovic, L., Lehman, M., Capp, A., Pryor, D., Harris, M., Nelson, C., Martin, J., Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J. Cancer Res. Clin. Oncol. 140 (2014), 2157–2162.
224. Davis, J.W., Nakanishi, H., Kumar, V.S., Bhadkamkar, V.A., McCormack, R., Fritsche, H.A., Handy, B., Gornet, T., Babaian, R.J., Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J. Urol. 179 (2008), 2187–2191 discussion 2191.
225. Aragon-Ching, J.B., Siegel, R.S., Frazier, H. 2nd, Andrawis, R., Hendricks, F., Phillips, M., Jarrett, T., Guebre-Xabiher, H., Patierno, S., Simmens, S.J., circulating tumor cells in biochemical recurrence of prostate cancer. Clin. Genitourin. Cancer 13 (2015), e341–345.
226. Thalgott, M., Rack, B., Maurer, T., Souvatzoglou, M., Eiber, M., Kress, V., Heck, M.M., Andergassen, U., Nawroth, R., Gschwend, J.E., Retz, M., Detection of circulating tumor cells in different stages of prostate cancer. J. Cancer Res. Clin. Oncol. 139 (2013), 755–763.
227. Resel Folkersma, L., San José Manso, L., Galante Romo, I., Moreno Sierra, J., Olivier Gómez, C., Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80 (2012), 1328–1332.
228. Kuske, A., Gorges, T.M., Tennstedt, P., Tiebel, A.K., Pompe, R., Preisser, F., Prues, S., Mazel, M., Markou, A., Lianidou, E., Peine, S., Alix-Panabieres, C., Riethdorf, S., Beyer, B., Schlomm, T., Pantel, K., Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci. Rep., 6, 2016, 39736.
229. Okegawa, T., Nutahara, K., Higashihara, E., Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J. Urol. 180 (2008), 1342–1347.
230. Goodman, O.B. Jr., Symanowski, J.T., Loudyi, A., Fink, L.M., Ward, D.C., Vogelzang, N.J., Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin. Genitourin. Cancer 9 (2011), 31–38.
231. Hoang, D.T., Iczkowski, K.A., Kilari, D., See, W., Nevalainen, M.T., Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget 8 (2017), 3724–3745.
232. Darshan, M.S., Loftus, M.S., Thadani-Mulero, M., Levy, B.P., Escuin, D., Zhou, X.K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S.T., Bander, N.H., Nanus, D.M., Giannakakou, P., Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71 (2011), 6019–6029.
233. Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., Mosquera, J.M., Montgomery, B., Taplin, M.E., Pritchard, C.C., Attard, G., Beltran, H., Abida, W., Bradley, R.K., Vinson, J., Cao, X., Vats, P., Kunju, L.P., Hussain, M., Feng, F.Y., Tomlins, S.A., Cooney, K.A., Smith, D.C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D.E., Morris, M.J., Solomon, S.B., Durack, J.C., Reuter, V.E., Gopalan, A., Gao, J., Loda, M., Lis, R.T., Bowden, M., Balk, S.P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E.Y., Mostaghel, E.A., Cheng, H.H., Mulcahy, H., True, L.D., Plymate, S.R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B.D., Schiffman, M., Nanus, D.M., Tagawa, S.T., Sigaras, A., Eng, K.W., Elemento, O., Sboner, A., Heath, E.I., Scher, H.I., Pienta, K.J., Kantoff, P., de Bono, J.S., Rubin, M.A., Nelson, P.S., Garraway, L.A., Sawyers, C.L., Chinnaiyan, A.M., Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
234. Attard, G., de Bono, J.S., Logothetis, C.J., Fizazi, K., Mukherjee, S.D., Joshua, A.M., Schrijvers, D., van den Eertwegh, A.J., Li, W., Molina, A., Griffin, T.W., Kheoh, T., Ricci, D.S., Zelinsky, K., Rathkopf, D.E., Scher, H.I., Ryan, C.J., Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin. Cancer Res. 21 (2015), 1621–1627.
235. Ristau, B.T., O'Keefe, D.S., Bacich, D.J., The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol. 32 (2014), 272–279.
236. Naoe, M., Ogawa, Y., Morita, J., Omori, K., Takeshita, K., Shichijyo, T., Okumura, T., Igarashi, A., Yanaihara, A., Iwamoto, S., Fukagai, T., Miyazaki, A., Yoshida, H., Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer 109 (2007), 1439–1445.
237. Gallagher, D.J., Milowsky, M.I., Ishill, N., Trout, A., Boyle, M.G., Riches, J., Fleisher, M., Bajorin, D.F., Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol. 20 (2009), 305–308.
238. Okegawa, T., Hayashi, K., Hara, H., Nutahara, K., Higashihara, E., Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int. J. Urol. 17 (2010), 254–258.
239. Karl, A., Tritschler, S., Hofmann, S., Stief, C.G., Schindlbeck, C., Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer. Eur. J. Med. Res. 14 (2009), 487–490.
240. Guzzo, T.J., McNeil, B.K., Bivalacqua, T.J., Elliott, D.J., Sokoll, L.J., Schoenberg, M.P., The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol. Oncol. 30 (2012), 44–48.
241. Rink, M., Chun, F.K., Minner, S., Friedrich, M., Mauermann, O., Heinzer, H., Huland, H., Fisch, M., Pantel, K., Riethdorf, S., Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 107 (2011), 1668–1675.
242. Soave, A., Riethdorf, S., Dahlem, R., von Amsberg, G., Minner, S., Weisbach, L., Engel, O., Fisch, M., Pantel, K., Rink, M., A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int. J. Cancer 140 (2017), 381–389.
243. Soave, A., Riethdorf, S., Dahlem, R., Minner, S., Weisbach, L., Engel, O., Fisch, M., Pantel, K., Rink, M., Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU Int. 119 (2017), 854–861.
244. Flaig, T.W., Wilson, S., van Bokhoven, A., Varella-Garcia, M., Wolfe, P., Maroni, P., Genova, E.E., Morales, D., Lucia, M.S., Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 78 (2011), 863–867.
245. Gazzaniga, P., Gradilone, A., de Berardinis, E., Busetto, G.M., Raimondi, C., Gandini, O., Nicolazzo, C., Petracca, A., Vincenzi, B., Farcomeni, A., Gentile, V., Cortesi, E., Frati, L., Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann. Oncol. 23 (2012), 2352–2356.
246. Gazzaniga, P., de Berardinis, E., Raimondi, C., Gradilone, A., Busetto, G.M., De Falco, E., Nicolazzo, C., Giovannone, R., Gentile, V., Cortesi, E., Pantel, K., Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int. J. Cancer 135 (2014), 1978–1982.
247. Busetto, G.M., Ferro, M., Del Giudice, F., Antonini, G., Chung, B.I., Sperduti, I., Giannarelli, D., Lucarelli, G., Borghesi, M., Musi, G., de Cobelli, O., De Berardinis, E., The prognostic role of circulating tumor cells (CTC) in high-risk non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer 15 (2017), e661–e666.
248. Alva, A., Friedlander, T., Clark, M., Huebner, T., Daignault, S., Hussain, M., Lee, C., Hafez, K., Hollenbeck, B., Weizer, A., Premasekharan, G., Tran, T., Fu, C., Ionescu-Zanetti, C., Schwartz, M., Fan, A., Paris, P., Circulating tumor cells as potential biomarkers in bladder cancer. J. Urol. 194 (2015), 790–798.
249. Nastaly, P., Ruf, C., Becker, P., Bednarz-Knoll, N., Stoupiec, M., Kavsur, R., Isbarn, H., Matthies, C., Wagner, W., Hoppner, D., Fisch, M., Bokemeyer, C., Ahyai, S., Honecker, F., Riethdorf, S., Pantel, K., Circulating tumor cells in patients with testicular germ cell tumors. Clin. Cancer Res. 20 (2014), 3830–3841.
250. Gorin, M.A., Verdone, J.E., van der Toom, E., Bivalacqua, T.J., Allaf, M.E., Pienta, K.J., Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nat. Rev. Urol. 14 (2017), 90–97.
251. Gradilone, A., Iacovelli, R., Cortesi, E., Raimondi, C., Gianni, W., Nicolazzo, C., Petracca, A., Palazzo, A., Longo, F., Frati, L., Gazzaniga, P., Circulating tumor cells and “suspicious objects” evaluated through CellSearch(R) in metastatic renal cell carcinoma. Anticancer Res. 31 (2011), 4219–4221.
252. Bluemke, K., Bilkenroth, U., Meye, A., Fuessel, S., Lautenschlaeger, C., Goebel, S., Melchior, A., Heynemann, H., Fornara, P., Taubert, H., Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol. Biomark. Prev. 18 (2009), 2190–2194.
253. Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., Xu, H., Wang, Z., Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. BMC Cancer, 15, 2015, 202.
254. van Dalum, G., Stam, G.J., Scholten, L.F., Mastboom, W.J., Vermes, I., Tibbe, A.G., De Groot, M.R., Terstappen, L.W., Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int. J. Oncol. 46 (2015), 1361–1368.
255. Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C., Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 58 (2012), 936–940.
256. Gorges, T.M., Stein, A., Quidde, J., Hauch, S., Rock, K., Riethdorf, S., Joosse, S.A., Pantel, K., Improved detection of circulating tumor cells in metastatic colorectal cancer by the combination of the CellSearch(R) system and the AdnaTest(R). PLoS One, 11, 2016, e0155126.
257. Li, Y., Gong, J., Zhang, Q., Lu, Z., Gao, J., Li, Y., Cao, Y., Shen, L., Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br. J. Cancer 114 (2016), 138–145.
258. Pernot, S., Badoual, C., Terme, M., Castan, F., Cazes, A., Bouche, O., Bennouna, J., Francois, E., Ghiringhelli, F., De La Fouchardiere, C., Samalin, E., Bachet, J.B., Borg, C., Ducreux, M., Marcheteau, E., Stanbury, T., Gourgou, S., Malka, D., Taieb, J., Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur. J. Cancer 79 (2017), 15–22.
259. Matsushita, D., Uenosono, Y., Arigami, T., Yanagita, S., Nishizono, Y., Hagihara, T., Hirata, M., Haraguchi, N., Arima, H., Kijima, Y., Kurahara, H., Maemura, K., Okumura, H., Ishigami, S., Natsugoe, S., Clinical significance of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. Ann. Surg. Oncol. 22 (2015), 3674–3680.
260. Reeh, M., Effenberger, K.E., Koenig, A.M., Riethdorf, S., Eichstadt, D., Vettorazzi, E., Uzunoglu, F.G., Vashist, Y.K., Izbicki, J.R., Pantel, K., Bockhorn, M., Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer. Ann. Surg. 261 (2015), 1124–1130.
261. Bidard, F.C., Huguet, F., Louvet, C., Mineur, L., Bouche, O., Chibaudel, B., Artru, P., Desseigne, F., Bachet, J.B., Mathiot, C., Pierga, J.Y., Hammel, P., Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann. Oncol. 24 (2013), 2057–2061.
262. Earl, J., Garcia-Nieto, S., Martinez-Avila, J.C., Montans, J., Sanjuanbenito, A., Rodriguez-Garrote, M., Lisa, E., Mendia, E., Lobo, E., Malats, N., Carrato, A., Guillen-Ponce, C., Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer, 15, 2015, 797.
263. Okubo, K., Uenosono, Y., Arigami, T., Mataki, Y., Matsushita, D., Yanagita, S., Kurahara, H., Sakoda, M., Kijima, Y., Maemura, K., Natsugoe, S., Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Eur. J. Surg. Oncol. 43 (2017), 1050–1055.
264. Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., Clack, G., Hughes, A., Blackhall, F., Valle, J.W., Dive, C., A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br. J. Cancer 106 (2012), 508–516.
265. Yang, J.D., Campion, M.B., Liu, M.C., Chaiteerakij, R., Giama, N.H., Ahmed Mohammed, H., Zhang, X., Hu, C., Campion, V.L., Jen, J., Venkatesh, S.K., Halling, K.C., Kipp, B.R., Roberts, L.R., Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology 63 (2016), 148–158.
266. Kelley, R.K., Magbanua, M.J., Butler, T.M., Collisson, E.A., Hwang, J., Sidiropoulos, N., Evason, K., McWhirter, R.M., Hameed, B., Wayne, E.M., Yao, F.Y., Venook, A.P., Park, J.W., Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer, 15, 2015, 206.
267. Schulze, K., Gasch, C., Staufer, K., Nashan, B., Lohse, A.W., Pantel, K., Riethdorf, S., Wege, H., Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int. J. Cancer 133 (2013), 2165–2171.
268. Naito, T., Tanaka, F., Ono, A., Yoneda, K., Takahashi, T., Murakami, H., Nakamura, Y., Tsuya, A., Kenmotsu, H., Shukuya, T., Kaira, K., Koh, Y., Endo, M., Hasegawa, S., Yamamoto, N., Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J. Thorac. Oncol. 7 (2012), 512–519.
269. Tanaka, F., Yoneda, K., Kondo, N., Hashimoto, M., Takuwa, T., Matsumoto, S., Okumura, Y., Rahman, S., Tsubota, N., Tsujimura, T., Kuribayashi, K., Fukuoka, K., Nakano, T., Hasegawa, S., Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin. Cancer Res. 15 (2009), 6980–6986.
270. Hou, J.M., Krebs, M.G., Lancashire, L., Sloane, R., Backen, A., Swain, R.K., Priest, L.J., Greystoke, A., Zhou, C., Morris, K., Ward, T., Blackhall, F.H., Dive, C., Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30 (2012), 525–532.
271. Hiltermann, T.J., Pore, M.M., van den Berg, A., Timens, W., Boezen, H.M., Liesker, J.J., Schouwink, J.H., Wijnands, W.J., Kerner, G.S., Kruyt, F.A., Tissing, H., Tibbe, A.G., Terstappen, L.W., Groen, H.J., Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23 (2012), 2937–2942.
272. Messaritakis, I., Politaki, E., Plataki, M., Karavassilis, V., Kentepozidis, N., Koinis, F., Samantas, E., Georgoulias, V., Kotsakis, A., Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. Lung Cancer 104 (2017), 16–23.
273. Messaritakis, I., Stoltidis, D., Kotsakis, A., Dermitzaki, E.K., Koinis, F., Lagoudaki, E., Koutsopoulos, A., Politaki, E., Apostolaki, S., Souglakos, J., Georgoulias, V., TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC). Sci. Rep., 7, 2017, 45351.
274. Krebs, M.G., Sloane, R., Priest, L., Lancashire, L., Hou, J.M., Greystoke, A., Ward, T.H., Ferraldeschi, R., Hughes, A., Clack, G., Ranson, M., Dive, C., Blackhall, F.H., Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29 (2011), 1556–1563.
275. Hanssen, A., Wagner, J., Gorges, T.M., Taenzer, A., Uzunoglu, F.G., Driemel, C., Stoecklein, N.H., Knoefel, W.T., Angenendt, S., Hauch, S., Atanackovic, D., Loges, S., Riethdorf, S., Pantel, K., Wikman, H., Characterization of different CTC subpopulations in non-small cell lung cancer. Sci. Rep., 6, 2016, 28010.
276. Yang, B., Qin, A., Zhang, K., Ren, H., Liu, S., Liu, X., Pan, X., Yu, G., Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in EGFR-mutant non-small-cell lung cancer patients. Oncol. Res., 25, 2017, 10.1007/s12253-12017-10195-12255.
277. Chakravarti, N., Prieto, V.G., Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl. Lung Cancer Res. 4 (2015), 743–751.
278. Ilie, M., Szafer-Glusman, E., Hofman, V., Long-Mira, E., Suttmann, R., Darbonne, W., Butori, C., Lalvee, S., Fayada, J., Selva, E., Yu, W., Marquette, C.H., Shames, D.S., Punnoose, E., Hofman, P., Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients. Oncotarget 8 (2017), 26112–26121.
279. Gabriel, M.T., Calleja, L.R., Chalopin, A., Ory, B., Heymann, D., Circulating tumor cells: a review of non-EpCAM-based approaches for cell enrichment and isolation. Clin. Chem. 62 (2016), 571–581.
280. Hanssen, A., Loges, S., Pantel, K., Wikman, H., Detection of circulating tumor cells in non-small cell lung cancer. Front. Oncol., 5, 2015, 207.
281. Hou, J.M., Krebs, M., Ward, T., Sloane, R., Priest, L., Hughes, A., Clack, G., Ranson, M., Blackhall, F., Dive, C., Circulating tumor cells as a window on metastasis biology in lung cancer. Am. J. Pathol. 178 (2011), 989–996.
282. He, S., Li, P., Chen, X., Yu, Z., Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases: a case report. Oncol. Lett. 6 (2013), 448–452.
283. Komine, K., Inoue, M., Otsuka, K., Fukuda, K., Nanjo, H., Shibata, H., Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary origin. Anticancer Res. 34 (2014), 3165–3168.
284. Liu, J.F., Kindelberger, D., Doyle, C., Lowe, A., Barry, W.T., Matulonis, U.A., Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol. Oncol. 131 (2013), 352–356.
285. Behbakht, K., Sill, M.W., Darcy, K.M., Rubin, S.C., Mannel, R.S., Waggoner, S., Schilder, R.J., Cai, K.Q., Godwin, A.K., Alpaugh, R.K., Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol. Oncol. 123 (2011), 19–26.
286. Poveda, A., Kaye, S.B., McCormack, R., Wang, S., Parekh, T., Ricci, D., Lebedinsky, C.A., Tercero, J.C., Zintl, P., Monk, B.J., Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol. Oncol. 122 (2011), 567–572.
287. Ni, T., Sun, X., Shan, B., Wang, J., Liu, Y., Gu, S.L., Wang, Y.D., Detection of circulating tumour cells may add value in endometrial cancer management. Eur. J. Obstet. Gynecol. Reprod. Biol. 207 (2016), 1–4.
288. Grobe, A., Blessmann, M., Hanken, H., Friedrich, R.E., Schon, G., Wikner, J., Effenberger, K.E., Kluwe, L., Heiland, M., Pantel, K., Riethdorf, S., Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin. Cancer Res. 20 (2014), 425–433.
289. He, S., Li, P., He, S., Long, T., Zhang, N., Fang, J., Yu, Z., Detection of circulating tumour cells with the CellSearch system in patients with advanced-stage head and neck cancer: preliminary results. J. Laryngol. Otol. 127 (2013), 788–793.
290. Bozec, A., Ilie, M., Dassonville, O., Long, E., Poissonnet, G., Santini, J., Chamorey, E., Ettaiche, M., Chauviere, D., Peyrade, F., Hebert, C., Benezery, K., Sudaka, A., Haudebourg, J., Selva, E., Hofman, P., Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 270 (2013), 2745–2749.
291. Nichols, A.C., Lowes, L.E., Szeto, C.C., Basmaji, J., Dhaliwal, S., Chapeskie, C., Todorovic, B., Read, N., Venkatesan, V., Hammond, A., Palma, D.A., Winquist, E., Ernst, S., Fung, K., Franklin, J.H., Yoo, J., Koropatnick, J., Mymryk, J.S., Barrett, J.W., Allan, A.L., Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck 34 (2012), 1440–1444.
292. Blom, A., Bhatia, S., Pietromonaco, S., Koehler, K., Iyer, J.G., Nagase, K., Paulson, K., Sabath, D.E., Nghiem, P., Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. J. Am. Acad. Dermatol. 70 (2014), 449–455.
293. Khan, M.S., Kirkwood, A.A., Tsigani, T., Lowe, H., Goldstein, R., Hartley, J.A., Caplin, M.E., Meyer, T., Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin. Cancer Res. 22 (2016), 79–85.
294. Khan, M.S., Kirkwood, A., Tsigani, T., Garcia-Hernandez, J., Hartley, J.A., Caplin, M.E., Meyer, T., Circulating tumor cells as prognostic markers in neuroendocrine tumors. J. Clin. Oncol. 31 (2013), 365–372.
295. Hida, T., Yoneta, A., Wakamatsu, K., Yanagisawa, K., Ishii-Osai, Y., Kan, Y., Kato, J., Yamashita, T., Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis. Australas. J. Dermatol. 57 (2016), 145–149.
296. Bande, M.F., Santiago, M., Muinelo-Romay, L., Blanco, M.J., Mera, P., Capeans, C., Pardo, M., Pineiro, A., Detection of circulating melanoma cells in choroidal melanocytic lesions. BMC. Res. Notes, 8, 2015, 452.
297. Roland, C.L., Ross, M.I., Hall, C.S., Laubacher, B., Upshaw, J., Anderson, A.E., Lucci, A., Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study. Melanoma Res. 25 (2015), 335–341.
298. Khoja, L., Shenjere, P., Hodgson, C., Hodgetts, J., Clack, G., Hughes, A., Lorigan, P., Dive, C., Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res. 24 (2014), 40–46.
299. Khoja, L., Lorigan, P., Zhou, C., Lancashire, M., Booth, J., Cummings, J., Califano, R., Clack, G., Hughes, A., Dive, C., Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J. Invest. Dermatol. 133 (2013), 1582–1590.
300. Bidard, F.C., Madic, J., Mariani, P., Piperno-Neumann, S., Rampanou, A., Servois, V., Cassoux, N., Desjardins, L., Milder, M., Vaucher, I., Pierga, J.Y., Lebofsky, R., Stern, M.H., Lantz, O., Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int. J. Cancer 134 (2014), 1207–1213.
301. Steen, S., Nemunaitis, J., Fisher, T., Kuhn, J., Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc. (Baylor Univ. Med. Cent.) 21 (2008), 127–132.